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Abstract
Background: Cholesterol homeostasis dysfunction has been reported to have role in the pathogenesis of
Alzheimer disease (AD). Therefore, changes in cholesterol metabolism in blood components may help to develop
new potential AD biomarkers. In this study changes in cholesterol metabolism-related gene expression genes were
evaluated in peripheral blood mononuclear cells (PBMCs) from AD subjects, their first degree relatives (FDR) and
two groups of age matched controls (C1 > 80 years, C2 < 60 years). The expression of three genes related to APP
processing was also determined.
Results: Results showed significantly different behavior (P = 0.000) in the expression of all analyzed genes among
the 4 groups. An inverse correlation emerged between the age of controls and the propensity of their PBMCs to
express selected genes. Moreover, when gene expression was evaluated in PBMCs from AD patients and compared
with that of PBMCs from healthy subjects of the same age, LDL-R and APP mRNAs were most abundant in AD as
compared C1 whereas SREBP-2 and particularly nCEH were present at much lower mRNA levels in AD-PBMCs. This
study describes for the first time a differential expression profile of cholesterol and APP related genes in PBMCs
from AD patients and their FDR.
Conclusions: We suggest that the expressions of cholesterol homeostasis and APP processing related genes in
PBMC could be proposed as possible biomarkers to evaluate AD risk. In addition, gene expression in PBMC could
be also used for diagnosis and development of therapeutic strategies as well as for personalized prediction in
clinical outcome of AD.
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Background
Alzheimer disease (AD) is a severe neurodegenerative
disorder characterized by loss of memory and cognitive
decline that at a cellular level, exhibits several histo-
pathological markers including beta-amyloid (Ab) pla-
ques, formed after sequential cleavage by b and g
secretases of the amyloid precursor protein (APP), neu-
rofibrillary tangles (NFTs) within neurons, and the loss
of synaptic connections manifested as brain atrophy
[1-3]. The prevalence of AD is expected to rise dramati-
cally in the next few decades, thus, it is a great challenge
to establish reliable surrogate markers to diagnose and
monitor the progression of this devastating disease.
However, the development of these biomarkers is com-
plicated not only for the variability in clinical features
and multiple molecular etiologies, but especially for the
impossibility to make analyses on brain in vivo. During
the last several decades, the knowledge pertaining to
brain cellular cholesterol homeostasis has greatly
increased and numerous studies have indicated that
changes in intracerebral cholesterol levels are involved
in the pathogenesis of AD and possibly other forms of
neuropathologies [4]. It has been demonstrated that
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increased cholesterol levels stimulate the activity of the
b-secretase (BACE-1) pathway, leading to an accumula-
tion of Ab peptides [5] On the other hand, it has been
also reported that Ab itself may affect cholesterol home-
ostasis by reducing intracellular free cholesterol (FC)
levels [6]. In CHO cells and various neuron-like cells
grown in culture, the decrease of cholesterol esters (CE)
either by genetic inactivation of acylCoA:cholesterol-
acyltransferase (ACAT-1), the intracellular enzyme that
catalyzes CE synthesis, or by pharmacological inhibition
of this enzyme, was associated with a decrease of Ab
secretion [7]. In addition, in an AD mouse model
ACAT inhibitors CP-113,818 and CI 1011 substantially
diminished amyloid plaque density [8,9]. Based on these
studies, it has been suggested that the ratio between FC
and total cholesterol (TC) is a primary regulator of the
APP processing, and that ACAT may be considered as a
drug target for therapeutic intervention against certain
form(s) of AD [10]. In this regard, the ablation of
ACAT-1 in AD-mice, was able to reduce more than
60% the full-length APP protein as well as its proteolytic
fragments, and to ameliorate cognitive deficits [11].
Because of the extremely high ratio between FC and CE
in the adult human brain, at the present it is difficult to
understand how ACAT modulates APP processing in
vivo, however, the aforementioned studies address cho-
lesterol homeostasis as a central component of neurode-
generative cascades, which can influence several aspects
of AD development. Thus, it seems that to prevent and
treat neurodegenerative conditions, research needs to
develop simple, inexpensive and rapid tools to measure
several biomarkers involved in the modulation of choles-
terol homeostasis in the brain. Unfortunately, the notion
that cholesterol in the brain is insulated from changes
in circulating cholesterol [12], limits the use of blood
samples for cholesterol biomarker discovery in brain. An
unbalance between FC and CE pools, similar to that
observed in neuron-like cells grown in culture and in
AD brain, however, was recently found by us in skin
fibroblasts [13] as well as in peripheral blood mononuc-
lear cells (PBMC) from AD patients and their first
degree relative [14,15]. We suggested that PBMCs may
be utilized as surrogate tissues to further investigate
potentially harmful effects of cholesterol changes in tis-
sues that are not otherwise easily accessible. In this
study, we investigated changes in mRNA levels of the
major proteins involved in: (1) cholesterol uptake: low
density lipoprotein receptor, LDL-R; (2) cholesterol neo-
synthesis and regulation: hydroxy-methyl-glutaryl coen-
zyme A reductase, HMGCoA-R, and the sterol
regulatory element binding protein-2, SREBP-2, a tran-
scription factor regarded as the main regulator of cho-
lesterol homeostasis; (3) cholesterol trafficking: caveolin-
1 (Cav-1) and ATP binding cassette-A, ABCA-1; (4)
cholesterol ester cycle: ACAT-1 and neutral cholesterol
ester hydrolase, nCEH; (5) Ab production: APP and
BACE-1 and (6) Ab degradation: neprilysin, in periph-
eral blood mononuclear cells (PBMCs) isolated from AD
patients, and from their first degree relative (FDR-AD).
As controls we utilized PBMCs from apparently healthy
subjects aged > 75 years (controls 1) and < 60 years
(controls 2) were employed as the normal counterparts.
It was our aim the identification of differentially
expressed genes and/or distinctive patterns of gene
expression which may help to better understanding AD
pathophysiology and to develop specific diagnosis and
effective therapy.
Results
Measurement of neutral lipids in PBMCs of AD and FDR-
AD subjects
We began to determine neutral lipids in PBMCs sepa-
rated from blood samples of 50 subjects: 13 subjects
apparently healthy, lacking of cognitive deficit, aged
between 81-87 years (C1), 12 subjects diagnosed with
late-onset probable AD, aged between 70-89 years (AD),
12 subjects apparently healthy, aged between 25-57
years (C2) and 13 FDR of AD subjects (FDR-AD) aged
between 40-63 years. Total neutral lipids were deter-
mined by staining freshly isolated PBMCs with Oil-red-
O (ORO), a lysochrome (fat soluble dye) widely used for
demonstrating the presence of neutral lipids (mostly
CE) which appear as red-stained cytoplasmic droplets.
ORO staining evidenced a consistent accumulation of
neutral lipids in cytoplasm of all AD-PBMCs compared
to C1 (Figure 1a). Two different pictures have indeed
been observed in FDR-AD (Figure 1a). Six out of 13 of
them (46%) exhibited neutral lipid pattern similar to
their AD affected relatives, while in 7 subjects, neutral
lipids were absent or very low resembling that of C2.
Quantization of red intensity in each image was also
determined using the public domain program Image J
1.42 and selecting a region of interest (ROI). The com-
parison of these pictures, by analysis of variance
(ANOVA), showed a significant difference (P = 0.000)
among the groups (Figure 1b). These results confirmed
that alterations of lipid metabolism in peripheral cells, i.
e. PBMCs, are associated with AD. It remains to be
established whether they are merely due to a defect in
ACAT activity, or rather they reflect differences in cho-
lesterol pools or in cellular cholesterol distribution.
mRNA levels of genes associated with cholesterol
homeostasis and APP processing in ex vivo PBMCs
To gain insights into the possibility that gene expression
data in blood cells may enable the identification of
potential new biomarkers for brain diseases including
AD, we next determined the mRNA levels of a number
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of genes associated with cholesterol homeostasis and
APP processing in ex vivo PBMCs from the 4 selected
groups (Figure 2). Analysis of variance (ANOVA)
showed significantly different behavior (P = 0.000) in
the expression of all analyzed genes between the groups
(Figure 3). Table 1 shows association between age and
genes involved in cholesterol and APP metabolism in
both controls (C1 + C2), and AD + FDR-AD, as mea-
sured by the Pearson correlation coefficient. A signifi-
cant inverse correlation emerged between the age of
healthy controls and the propensity of their PBMCs to
express selected genes. With the exception of ACAT-1
and ABCA-1, the mRNA levels of all other genes exam-
ined were decreased significantly (p < 0.05) in PBMCs
of old subjects (C1) when compared to that of middle-
aged volunteers (C2) (Figure 4a). However, when results
obtained from AD patients were compared to that from
C2 (AD vs C2) (Figure 4c), the accumulation of CE was
associated with an increased expression of SREBP-2 and
APP and with a decrease of ABCA-1 and ACAT-1. In
addition, LDL-R and APP mRNAs were most abundant
(p < 0.05) in AD compared to C1 (Figure 4b.) whereas
SREBP-2 and particularly nCEH were present at much
lower mRNA levels in AD PBMCs. No significant
changes in the expression of the other genes were
observed between AD and C1 groups (Figure 4b). A par-
tially different scenario was observed when FDR-AD was
compared to C1, C2 and AD groups (Figures 4e, d and
4f). Compared to C2, FDR-AD PBMCs exhibited lower
expression of SREBP-2, Cav-1, nCEH, ABCA-1 as well
as BACE-1, APP and neprylisin (Figure 4d), a pattern of
gene expression similar to C1 group with the exception
of SREBP-2, nCEH and Cav-1 mRNA levels that were
significantly (p < 0.05) decreased in FDR-AD compared
to C1 (Figure 4e). Compared to AD, FDR-AD subjects
have lower CEs levels and lower mRNA APP levels; but
higher mRNA levels of ACAT-1 (Figure 4f).
Discussion
Histochemical and immunohistochemical detection of
Ab in postmortem brain tissue still remains the most
accurate and definitive means by which AD is
Figure 1 ORO staining of cytoplasmic neutral lipids. Freshly
isolated PBMCs were stained with ORO to demonstrate neutral
lipids and counterstained with haematoxylin for nuclei. Cells were
then examined by light microscopy and two different fields per
sample were imaged. Red ORO intensity was measured in these
two fields using NIH Image J software. Panel (a) shows
representative images of ORO stained (on the left) and their
corresponding ROI (on the right). Panel (b) shows quantization of
red intensity expressed as the percentage of pixel intensity ± SD⁄
total area of each image. Analysis of variance (ANOVA) shows
significant statistically differences among the four groups (P =
0.000).
Figure 2 Representative blots of mRNA levels of cholesterol
metabolism and APP processing-related genes. Total mRNA was
extracted from PBMCs of the selected groups. mRNA levels of
indicated genes were then determined by RT-PCR using appropriate
primer sets. Specific bands were detected after addition of a
chemiluminescent substrate.
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diagnosed. Starting from the notion that AD neurons
inappropriately enter the cell cycle without to complete
it, recent studies have proposed neuronal dysfunction
and death secondary cell cycle abnormalities, as sources
of potential AD biomarkers [16]. Similarly, oxidative
damage to various proteins, nucleic acids and other
compounds found early in AD neurons, probably arising
from mitochondrial abnormalities, has been also pro-
posed as a biomarker of AD risk [1,17,18]. In addition,
more recently, scientists from Pittsburgh University,
have developed a radio fluorinated positron emission
tomography (PET) probe, 2-(1-{6-[(2-[F 18]fluoroethyl)
(methyl)amino]-2-naphthyl}ethylidene)malononitrile ([F-
18]FDDNP), having an high binding affinity for amyloid
and amyloid-like structures, for detection of in vivo
brain imaging that allows to distinguish between AD
patients and healthy controls [19]. The rational was that
AD begins with abnormal processing of APP, which
leads to deposits of b- amyloid (Ab) in the neocortical
and subcortical regions of the brain [3]. Although
undoubtedly suggestive all the above strategies have
restricted applicability and are not suitable for routine
use, and hence, the development of techniques non-
invasive, simple, cheap, using easily accessible samples,
remains urgently needed for early diagnosis of AD. A
large body of evidence now suggests that APP
Figure 3 Densitometric analysis of mRNA levels of target genes normalized for the endogenous b-actin. mRNA levels were quantified by
using NIH Image 1.63 program (Scion Image). Data values are represented as mean ± SD for each group. *Statistical analysis performed by using
the one-way ANOVA test showed highly significant differences among the groups (P = 0.000 for all genes, with the exception of ACAT-1 for
whom the significance was P = 0.006).
Table 1 Pearson’s correlation coefficient (age vs mRNA
levels of selected genes)
C1 + C2 (n.25) AD + FDR-AD (n.25)
Neprilysin r = -0,8992 r = -0,2233
p = 0,000 p = 0,283
ABCA-1 r = -0,3503 r = 0,2457
p = 0,086 p = 0,236
ACAT-1 r = -0,7171 r = -03421
p = 0,000 p = 0,094
APP r = -0,5171 r = 0,4477
p = 0,008 p = 0,025
BACE-1 r = -0,5849 r = -0,3629
p = 0,002 p = 0,075
Cav-1 r = -0,6192 r = 0,0718
p = 0,001 p = 0,733
HMGCoA-R r = -0,4843 r = -0,4748
p = 0,014 p = 0,016
LDL-R r = -0,8361 r = -0,6829
p = 0,000 p = 0,000
nCEH r = -0,7544 r = -0,0151
p = 0,000 p = 0,943
SREBP-2 r = -0,7633 r = -0,2629
p = 0,000 p = 0,204
Significant statistical differences were indicated in bold
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Figure 4 Schematic representation of the data collected from the mRNA quantifications. The schemes represent the expression level,
cellular compartment and metabolic network position of genes linked to cholesterol homeostasis and to APP processing. The arrows (↑↓)
denote the significant (P < 0.05) differences (increase or decrease, respectively) between the two indicated groups, obtained by applying a
Bonferroni’s multiple comparison test following ANOVA.
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metabolism is affected by alteration of the lipid micro-
environment, however, relative few studies in this matter
have been performed in humans where an important
barrier to identify molecular biomarkers was the inac-
cessibility to brain samples [20]. Thus, keeping these
questions in mind it would be useful to find a noninva-
sive source of nucleic acids to explore the role of genes
involved in cholesterol homeostasis in the context of
human APP processing. An important component in
AD and cholesterol metabolism research concerns the
role of the isoforms (ε2,ε3,ε4) of apolipoprotein E
(ApoE), a plasma protein involved in the transport of
cholesterol in the central nervous system. The presence
of ApoE ε4 isoform, determined by using DNA from
PBMC, has been repeatedly proposed as a risk factor for
AD [21,22]. However, the use of ApoE genotype as a
diagnostic test in symptom-free individuals has limited
applicability since it cannot predict with certainty when,
or if, an individual with ApoE ε4/4 will get AD. Periph-
eral tissues suitable for providing useful molecular mar-
kers for diagnosis of AD include skin fibroblasts,
platelets, lymphocytes [23]. A previous our study show-
ing a significant higher concentration of neutral lipids in
PBMCs from AD patients and in some of their FDR[15]
suggested that this kind of sample could be applied to
perform studies on lipid-related molecular targets
involved in AD. In this sense, the current experimental
study has specifically utilized PBMCs collected by simple
blood samples to assess the expression of a large number
of genes correlated to cholesterol homeostasis and APP
processing in AD patients and their younger FDR. Our
results showed that, during physiological aging, PBMCs,
despite of a general decline of cholesterol turnover; retain
the molecular mechanisms responsible for the regulation
of intracellular cholesterol levels. These results are in
agreement with the notion that cholesterol turnover rela-
tively high in the developing brain, strongly declines to a
very low level in the aging state [24]. In addition, consis-
tent with the notion that at the molecular level, intracel-
lular cholesterol regulates APP processing and Ab
production [25], the age-related decline in cholesterol
turnover was closely associated with an age-related
decrease in the expression of genes normally involved in
APP processing. However, when gene expression was
evaluated in PBMCs from AD patients and compared
with that of PBMCs from healthy subjects of the same
age (C1), LDL-R and APP mRNAs were most abundant
in AD compared to C1 whereas SREBP-2 and particularly
nCEH were present at much lower RNA levels in AD-
PBMCs. These results suggested that at least some of
physiologic cholesterol homeostatic mechanisms are
impaired in AD patients and that these altered mechan-
isms are correlated with an increased gene expression of
APP. In addition, they provide indirect evidence that
besides ACAT1, nCEH, the enzyme responsible for
hydrolysis of CE, plays a major role in neutral lipids accu-
mulation observed in AD-PBMCs. The elevated steady-
state mRNA levels of APP observed in AD-PBMCs may
be responsible for the increased Ab production observed
in vitro and in vivo in AD models [26,27]. It remains
uncertain whether and how BACE1 is associated with
aging or neurodegenerative disease since under our
experimental conditions BACE1 mRNA levels signifi-
cantly decreased during physiological aging and beside
the increase in the expression of APP, they remain
unchanged in AD-PBMCs. In this study, we also showed
that in AD-FDR-PBMCs, several cholesterol related
genes are regulated in the same direction of those
involved in APP processing: lower expression of SREBP-
2, Cav-1, nCEH, ABCA1 as well as that of BACE1, APP
and neprylisin were observed in AD-FDR compared to
C1. Compared to AD, mRNA expression of ACAT1 in
AD-FDR appears to negatively correlate with APP
mRNA levels, a pattern of gene expression similar to C1
group with the exception of SREBP2, nCEH and Cav 1
mRNA levels that were significantly decreased in AD-
FDR compared to C1.
Conclusions
The current study demonstrates that the use of circulat-
ing mononuclear cells in the search of transcriptional
biomarkers in the context of neurodegenerative disorders
is feasible. Moreover, it reported for the first time a dif-
ferential expression profile of cholesterol and APP related
genes in PBMCs from AD patients and their FDR. This is
of particular relevance given the current view that genetic
factors play an important role in many cases of sporadic
AD [28]. Even though these findings should be corrobo-
rated in future studies, the expressions of cholesterol
homeostasis and APP processing related genes in PBMC
could be proposed as possible biomarkers to evaluate AD
risk. In addition, gene expression in PBMC could be also
used for diagnosis and development of therapeutic strate-




Blood samples were obtained from 50 subjects randomly
selected from a list of 400 subjects that were enrolled in
a pre-existing study [14]. They were divided into four
groups according to age: C1, old normal subjects (mean
age 83.8 ± 1.6 years); C2, middle-age normal subjects
(mean age 48.6 ± 10.5 years); FDR-AD, first degree rela-
tives of AD patients without clinical symptoms (51.40 ±
10.3 years); AD, patients with clinical evidence of
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neuropathy (80.1 ± 5.9 years). Informed written consent
was obtained from all patients and healthy controls
before initiating the study, according to the policies of
the hospital’s Institutional Review Boards. Individuals
included in this study were enrolled at the Geriatric
Units of Aziende Ospedaliero-Universitarie and ASL 8
of Cagliari (Italy). Control subjects were healthy volun-
teers and none of them was a relative or caregiver of
the AD patients or seeking medical care for any reason.
Subjects with neoplastic or hematological disorders,
recent infections or surgery, severe hepatic or renal fail-
ure, myocardial infarction or cranial trauma in the pre-
vious 6 months, or who had received statins,
antineoplastic, corticosteroid, or immunosuppressive
drug treatments were not included in the study. The
diagnosis of probable AD was made according to the
criteria developed by National Institute of Neurological
and Communicative Disorders and Stroke (NINCDS)
and the Alzheimer’s Disease and Related Disorders
Association (ADRDA). For AD, routine clinical and
laboratory evaluation was performed to exclude other
causes of cognitive impairment and all subjects received
neuropsychological tests, such as the Mini-Mental State
Examination (MMSE). To assess the severity of the cog-
nitive impairment in AD patients, the Reisberg Global
Deterioration Scale (GDS) was also used. Abnormal
GDS levels start from level 3 and maximal deterioration
grade corresponds to level 7. Patient evaluation included
medical history, physical and neurological examinations,
laboratory blood tests to rule out metabolic causes of
dementia (thyroid hormones, vitamin B12, and erythro-
cyte sedimentation rate), and brain neuroimaging (com-
puted tomography and/or magnetic resonance).
Cell types and culture conditions
PBMCs were obtained by centrifuging blood samples at
600 g for 15 min. After centrifugation, plasma was
removed and the buffy coat was collected, and PBMCs
separated by Ficoll-Hypaque density gradient. Cells were
then suspended (1 × 106 cells ⁄ ml) in RPMI-1640 and
processed immediately (ex vivo) for lipid staining or fro-
zen at -80°C for mRNA.
Neutral lipid staining
Cells cultured as described above were treated with iso-
propyl alcohol (60%), washed, stained in oil red O
(ORO) for NL and counterstained with Mayer’s haema-
toxylin. Stained cells were examined by light micro-
scopy. Cytoplasmic red-stain intensity indicating neutral
lipid accumulation was quantified using Image J soft-
ware (National Institutes of Health, United States). ORO
intensity was calculated as percentage of positively
stained area (pixels/μm2) obtained by manually selecting
one region of interest (ROI).
Reverse-transcriptase polymerase chain reaction (RT-PCR)
and Southern blotting
mRNA levels for low density lipoprotein receptor
(LDLR), hydroxy-methyl-glutaryl coenzyme A reductase
(HMGCoA-R), sterol regulatory element-binding pro-
tein-2 (SREBP-2), ATP-binding cassette A (ABCA1),
acylCoA-cholesterol acyltransferase (ACAT-1), neutral
cholesterol ester hydrolase (nCEH), and caveolin-1 (cav-
1), were evaluated by reverse transcription polymerase
chain reaction (RT-PCR) using appropriate primer sets.
We chose to utilize this technique since our experience
indicates that it can be set up rapidly in a clinical
laboratory, and provide sensitive and specific results at
relatively low cost. Real-time PCR, by using fluorescently
labeled oligonucleotide probes, allows to detect and
quantitate a specific PCR product in real time. However,
it is difficult to design and requires more expensive
laboratory equipment. Total RNA was extracted from
approximately 106 cells using TRIZOL reagent (Invitro-
gen Corporation, Carlsbad, CA, USA). Equal amounts of
total RNA (1 μg) were reverse transcribed into cDNA
using the random hexamer method and amplified by
PCR in presence of specific primers, according to the
manufacturer’s instructions (GeneAmp RNA PCR Kit;
Perkin-Elmer Cetus, Norwalk, CT, USA). Amplicons
were labelled during PCR, with digoxigenin-11-dUTP
(Roche Applied Science, Mannheim, Germany), immu-
nodetected with anti-digoxigenin antibodies conjugated
to alkaline phosphatase (Roche Applied Science) and
visualized with chemiluminescent substrate CSPD.
Intensity of autoradiographic bands was measured after
exposure to X-ray film using Kodak Digital Science
Band Scanner Image Analysis System (Kodak, Rochester,
NY, USA). Specific bands were detected and analyzed by
NIH Image 1.63 program (Scion Image, Frederick, MD,
USA). Amounts of PCR products for each target mRNA
was normalized by using b-actin as housekeeping gene.
Statistical analysis
Data are reported as mean ± standard deviation (SD).
Statistical calculations were performed using statistical
analysis software Origin 8.0 version (Microcal Inc,
Northampton, MA, USA). Statistical comparisons
between the four groups were made by using a one-way
ANOVA and where appropriate a post hoc Bonferroni
test and Pearson correlation coefficient. A probability of
p < 0.05 was considered statistically significant.
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